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OUTCOME OF SLEEPINESS AND FATIGUE SCORES 
IN OBSTRUCTIVE SLEEP APNEA SYNDROME
PATIENTS WITH AND WITHOUT RESTLESS LEGS 
SYNDROME AFTER NASAL CPAP
Raimundo Nonato Delgado Rodrigues1, Aída Alexandra Alvim de Abreu e Silva
Rodrigues2, Riccardo Pratesi3, Marília Miranda Fortes Gomes4, 
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ABSTRACT - Background and Purpose: The association of obstructive sleep apnea syndrome (OSAS) and
restless legs syndrome (RLS) has been reported in the literature for many years. Both conditions may be
responsible for fatigue and somnolence complaints secondary to nocturnal sleep disruption. The primary
concern of this study is to evaluate the outcome of fatigue and daytime sleepiness symptoms at baseline
and after continuous positive air pressure (CPAP) treatment in OSAS patients with and without RLS. Method:
A prospective and comparative study between a group of 13 patients with OSAS and a group of 17 patients
with OSAS+RLS. Laboratory blood tests and polysomnography were performed at baseline. The Epworth
Sleepiness Scale (ESS) and the Pichot’s questionnaire of fatigue/depression (PIC) were applied before and
after 3 months of CPAP treatment. Results were compared. Results: No significant differences were found
on PSG and laboratory results at baseline. Both groups had similar ESS and PIC scores at baseline (p=0.73
and 0.08, respectively). After n-CPAP, OSAS+RLS patients showed higher ESS and PIC scores (p=0.017 and
0.03, respectively). Conclusions: Despite a favorable general response, n-CPAP seemed less effective in
treating fatigue and sleepiness in the OSAS+RLS group. 
KEY WORDS: OSAS, RLS, fatigue, sleepiness, ESS, Pichot.
Evolução dos índices de sonolência e fadiga em pacientes com síndrome da apnéia obstrutiva
do sono portadores ou não de associação com síndrome das pernas inquietas após CPAP nasal
RESUMO - Objetivo: A associação síndrome de apnéia obstrutiva do sono / síndrome de pernas inquietas
(SAOS-SPI) tem sido mencionada na literatura há muito. Ambas podem ser responsáveis por queixas de
fadiga e sonolência secundárias à fragmentação do sono noturno. O objetivo deste estudo é avaliar a
evolução dos sintomas de fadiga e sonolência diurna excessiva antes e após o tratamento com pressão
aérea positiva contínua (CPAP) em pacientes portadores de SAOS, com e sem SPI. Método: Estudo prospec-
tivo e comparativo entre um grupo de 13 pacientes com SAOS e um grupo de 17 com SAOS +SPI. Exames
laboratoriais e polissonografia (PSG) foram realizados no início do estudo. A escala de sonolência de Epworth
(ESE) e o questionário de fadiga/depressão de Pichot (PIC) foram aplicados antes do tratamento com CPAP
e 3 meses após. Os resultados foram comparados. Resultados: No início do estudo não foram encontradas
diferenças significativas na avaliação laboratorial e PSG. Ambos os grupos apresentavam inicialmente pon-
tuação semelhante na avaliação da ESE e PIC (p=0,73 e 0,08, respectivamente). Após CPAP, os pacientes
SAOS+SPI apresentaram maiores ESE e PIC (p=0,017 e 0,03, respectivamente). Conclusão: Apesar de respos-
ta inicial favorável em ambos os grupos, o CPAP foi aparentemente menos eficaz na redução das queixas
de fadiga e sonolência nos pacientes apnéicos com associação a SPI. 
PALAVRAS-CHAVE: SAOS, síndrome das pernas inquietas, fadiga, sonolência, escala de sonolência de
Epworth, Pichot.
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The association of obstructive sleep apnea syn-
drome (OSAS) and restless legs syndrome (RLS) has
been described for many years1,2. As both conditions
are frequent in the general population some diffi-
culties in differential diagnosis may arise since both
greatly disrupt nocturnal sleep, causing fatigue, limb
motor hyperactivity and daytime sleepiness3. In addi-
tion, some sleep laboratories may not have surface
electromyographic analysis of the anterior tibialis
muscle as a routine procedure during polysomnogra-
phies and therefore many nocturnal limb movements
(seen in about 85% of RLS patients4) may easily pass
unnoticed or be attributed only to respiratory effort5.
In fact, the details of that interesting association have
not been fully elucidated. For instance, the need to
treat both conditions simultaneously and their indi-
vidual influence on daytime sleepiness and fatigue
complaints are not fully understood. 
A common relationship has been suggested, how-
ever, related to a possible dysfunction of brainstem
centers2. Nonetheless, to our knowledge, there is no
description or clear evidence of a central nervous sys-
tem disturbance resultant from OSAS and RLS in a
same patient. Furthermore, the frequent concomi-
tant occurrence of metabolic syndrome in OSAS pa-
tients6,7 constitutes another important causative fac-
tor (i.e. relative iron overload) for limb motor abnor-
malities8. 
On the other side it is interesting to notice that
continuous positive air pressure (CPAP) treatment
may contribute to the reduction of fatigue and sleepi-
ness complaints in RLS patients with associated OSAS9.
Therefore, this study aimed at evaluating possi-
ble differences in sleepiness and fatigue response
patterns, before and after CPAP treatment, between
OSAS and OSAS+RLS-associated patients. In addition,
we described this association in terms of its clinical,
laboratory and polysomnographic features.
METHOD
Subjects – Seventeen OSAS patients, who met the diag-
nostic criteria for RLS (12 men and 5 women, mean age: 52±
10 years, range: 29-69), were consecutively identified9-11. In
addition, 13 patients presenting only OSAS (10 men and 3
women, mean age: 54±4.8 years, range: 45-62) were also
selected. Patients had been admitted to the Strasbourg
University Sleep Disorders Unit for the initial OSAS workup
and entered the study group after informed consent was
obtained and the whole protocol received the approval of
our Institution´s Ethics Committee. All 30 patients present-
ed periodic leg movements (PLM) as well, except one
(belonging to the OSAS group). 
OSAS diagnosis was determined according to the fol-
lowing criteria: snoring, excessive daytime sleepiness and
an apnea-hypopnea index greater than five events per hour
of sleep. PLM diagnosis was made using the parameters
described by Coleman12, while RLS was clinically determined
employing international criteria13. All patients had been
diagnosed with OSAS, RLS or PLM for the first time and had
never received previous treatment for any of these disor-
ders. Patients were divided into two groups: one comprised
of OSAS patients (n=13) and the second of OSAS+RLS-asso-
ciated patients (n=17).
General procedure – The protocol used in this study has
been object of a previous publication where further details
can be found9. Laboratory blood tests were performed in
both groups, including blood glycemia, iron metabolism
(serum transferrin and ferritin), TSHUs (thyroid stimulating
hormone-ultra-sensitive) and T4 dosages. Body mass index
(BMI) was also determined in all subjects. 
A polysomnographic assessment (PSG) was conducted
during a 4 night period spent at the Sleep Unit: (1) one
night for habituation to the laboratory settings, (2) one for
diagnostic purposes (polysomnographic night), (3) one for
nasal-CPAP titration, and (4) one for employing nasal-CPAP
with a fixed pressure, as determined during the previous
night. The polygraphic digital systems used comprised of
two Brainnet® Medatec and an Alice® 4 Respironics both
provided with a pneumotachograph (Tyco-Healthcare-Pu-
ritan Bennett®) or a nasal canula coupled to a pressure
transducer (Protech® Salter Labs) and an esophageal pres-
sure sensor or a thoracic-abdominal strain gauge. Limb EMG
was detected via surface electrodes placed over the right
and left tibialis muscle. Biological calibration was held pri-
or to recording and data were digitally stored and ana-
lyzed off-line. PLM were scored according to Coleman’s cri-
teria12.
Sleep was visually scored according to Rechtschaffen
and Kales criteria14. Microarousal criteria were those de-
scribed by ASDA (later AASM)15.
Additional sleep parameters were included, defined as
follows:
– Total sleep time (TST): time between the beginning and
end of sleep (TSP) minus the time spent awake during
the night;
– Sleep efficiency (SE): TST during the entire the record-
ings expressed as percentages;
– Percentage of stages 1 and 2 (PS 1-2): time spent in
stages 1 and 2 during the TST;
– Percentage of stages 3 and 4 (PS 3-4): time spent in
stages 3 and 4 during the TST;
– Percentage of REM (PREM): time spent in rapid-eye
movement sleep during the TST;
– Index of arousals (IAr): total number of microarousals
per hour of sleep;
– Apnea-hypopnea index (AHI): number of respiratory
events occurring per hour of sleep;
– PLM index (PLMi): number of periodic leg movements
occurring per hour of sleep.
Subjective daytime sleepiness and fatigue evaluation –
The Epworth Sleepiness Scale (ESS) scores16 were used to
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evaluate the patients’ level of daytime sleepiness, while
fatigue was measured employing the Pichot questionnaire
(PIC)17. The later is a practical 24-item self-rating account
with three homogeneous sub-scales of 8 items each which
measure depressive mood, asthenia-fatigue and anxiety
parameters, respectively. The asthenia-fatigue scale was
used, consisting of 8 questions scored progressively from
“0” (not at all) to “4” (extremely) (Table 1). Three months
after initiating n-CPAP treatment, all patients returned to
the Sleep Unit on an outpatient basis and had their day-
time sleepiness and fatigue re-evaluated by applying the
questionnaires described above.
Statistical analysis – Statistical analyses were performed
using SPSS for Windows, v.13.0. Mann-Whitney tests were
used to compare biometric, laboratory and polysomno-
graphic data. Data before and after n-CPAP treatment were
compared via Wilcoxon tests. Statistical significance was
set at p<0.05.
RESULTS
Patient characteristics – Both groups presented a
wide range of OSAS severity. Mean apnea-hypopnea
index was 56±35/h for group 1 and 44±27/h for group
2 (p=0.14), and BMI was 34.7±9 Kg/m2 for group 1
and 34±8 Kg/m2 for group 2 (p=0.81). All subjects had
low sleep efficiencies (mean: group 1 - 69±16%,
group 2 - 72±12%; p=0.54) and a high microarousal
index (mean: group 1 - 67±28/h, group 2 - 44±20/h;
p=0.11). Age (p=0.5) and gender (23.1% and 29.4%
women in group 1 and 2, respectively) did not differ
significantly between the two groups.
Clinical and laboratory characteristics – The base-
line biochemical profile (Table 2) of both groups was
not significantly different. Polysomnographic and n-
CPAP data are presented in Table 3. 
Sleepiness, PLM index and fatigue – Similar base-
line ESS scores were observed between the two
groups (p=0.73).
Following 3 months of n-CPAP treatment, ESS
scores decreased significantly. In OSAS patients, the
mean score of 10.5±4.6 observed prior to n-CPAP treat-
ment was reduced to 4.7±4.9 after treatment
(p=0.004). Similarly, the mean score of 10.6±4.8 in
OSAS+RLS patients decreased to 7.4±3.5 (p=0.014). In
addition, final ESS scores after n-CPAP differed signif-
icantly between groups (p=0.017). This finding may
suggest that n-CPAP treatment was less efficient at
improving daytime sleepiness in OSAS+RLS patients.
Furthermore, periodic movements of OSAS sub-
jects ranged from 0-164 (mean PLM index: 15.7±
27.2/h), while in the OSAS+RLS group the PLM range
was that of 3-127 (mean PLM index: 5.1±3.4/h; p=
0.51).
Via Pichot’s questionnaire we observed that fa-
tigue scores were similar in both groups before treat-
ment (Table 4). Scores decreased significantly, how-
ever, after n-CPAP treatment within both groups, par-
ticularly in the OSAS+RLS group (Table 4). None-
theless, OSAS+RLS patients’ final scores were still
higher than those of the remaining subjects (OSAS
group).
DISCUSSION
OSAS+RLS associations are observed in only 2.0-
8.3% of OSAS patients18-20. Such small prevalence may
be due, however, to the fact that RLS is in itself a
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Table 1. Pichot’ s questionnaire: items measuring the asthenia-
fatigue dimension.
1) I feel short of stamina 
2) Everything I do requires a huge effort 
3) I have a feeling of weakness in certain parts of my body 
4) My arms or legs are heavy 
5) I feel tired for no reason 
6) I feel like lying down and resting 
7) I have difficulty to concentrate 
8) I feel discouraged, my arms and legs are sore and heavy 
Table 2. Baseline biochemical profile of OSAS and OSAS+RLS patients.
Biochemical parameter Normal values Group 1 (OSAS) Group 2 (OSAS+RLS) p 
TSH (mUI/I) 0.15-4.5 1.7±0.8 1.5±0.5 0.23
T4 (ng/I) 11.6-26 16.3±2.5 15.4±2.69 0.23
Glucose (mmol/I) 4.1-5.9 6.5±3.1 6.2±1.1 0.36
Transferrin (g/I) 1.68-2.7 (women)
1.70-2.8 (men)
2.5±0.4 2.3±0.67 0.11
Ferritin (ug/I) 14-186 (women)
32-284 (men)
156.9±130.4 274.5±245.8 0.17
TSH, thyroid stimulating hormone; T4, thyroxin hormone.
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highly under-diagnosed condition21. In this context,
the present study aimed at determining if the occur-
rence of RLS was associated to a clinically distinct
OSAS profile or to a specific response of daytime
sleepiness and fatigue complaints to n-CPAP thera-
py in two groups of patients with and without the
association OSAS+RLS.
Our results indicated that OSAS and OSAS+RLS
patients had similar baseline biochemical and bio-
metric profiles. In fact, the concomitant occurrence
of obesity, hyperglycemia or insulin resistance and
high ferritin levels in OSAS patients may suggest an
association to a metabolic syndrome or syndrome
“X”6. Some authors have even suggested that the
definition of metabolic syndrome should be broad-
ened to include OSAS22. In addition, serum ferritin
levels are considered to be one of the main determi-
nants of blood glucose and a good marker of insulin
resistance23. 
Importantly, polysomnographic data indicated
that sleep quality tended to be low for all patients.
In addition, sleepiness evaluation, respiratory distur-
bance index, PLM index and therapeutic positive pres-
sure levels determined during the titration night were
also similar in both groups. Thus, no major baseline
clinical or polysomnographic differences were ob-
served in the OSAS patients, regardless of a possible
association with RLS. 
Similarly, subjective baseline daytime sleepiness,
evaluated by the ESS, did not differ among both
groups. Furthermore, significant improvements in
the ESS scores were observed in both groups follow-
ing n-CPAP treatment for 3 months, consonant with
previous findings24. Such improvement is thought to
occur in response to a reduction in sleep fragmenta-
tion, which stabilizes sleep structure, re-establishes
correct oxyhemoglobin blood levels and decreases
respiratory effort leading to a more refreshing night
sleep25. However, OSAS+RLS patients presented high-
er ESS scores, relative to OSAS subjects, regardless of
the general improvement in sleepiness. Such result
may suggest that these patients respond less favor-
ably to n-CPAP therapy. To our knowledge, this is the
first study to report that.
Similar baseline fatigue symptoms were found in
both groups, although OSAS+RLS subjects present-
ed higher absolute scores on the Pichot´s question-
naire (16.6±7.3), compared to OSAS patients (11.7±
6.6). In general, all patients responded well to n-CPAP
therapy, with an important decrease in fatigue scores.
When evaluated after the third month of treatment,
OSAS+RLS patients still demonstrated higher fatigue
scores. 
Fatigue, like somnolence, is frequently viewed as
a consequence of non-restorative sleep26, respond-
ing favorably to n-CPAP treatment in OSAS27,28. The
exact etiological generator of fatigue is still not clear,
although many possible sources have been suggest-
ed, notably the brainstem, hypothalamus, autonom-
ic nervous system and the neuroendocrine system29.
Abnormal P300 latencies are considered a good tool
for assessing fatigue symptoms29. 
Table 3. Polysomnographic and n-CPAP data of OSAS and OSAS+RLS patients.
Group 1 (OSAS) Group 2 (OSAS+RLS) p
TST (hours) 4.2±1.5 4.8±0.7 0.29
SE (%) 69±0.16 72±0.12 0.54
PSI-2 (%) 71.34±16.92 70.34±22.38 0.57
PS3-4 (%) 13.74±11.75 14.65±9.78 0.81
PREM (%) 14.91±8.43 9.12±6.96 0.11
IAr (number/h) 67.38±28.1 44.54±19.97 0.11
IAH (number /h) 56.11±35.25 44.26±27.5 0.41
n-CPAP (cmH2O) 9.69±2.92 9±2.93 0.5
TST, total sleep time; SE, sleep efficiency; PS1-2, percentage of stages 1 and 2; PS3-4, percentage
of stages 3 e 4; PREM, percentage of REM; IAr, index of arousals; lAH, apnea-hypopnea index; 
n-CPAP, positive pressure level.
Table 4. Fatigue scores observed before and after n-CPAP treat-
ment.






PIC (before CPAP) 11.7±6.6 16.6±7.3 0.08
PIC (after CPAP) 5.1±6.1 10.1±6.4 0.03
p (within-group) 0.008 0.001
PIC, Pichot’s questionnaire.
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In addition, our findings seem to suggest that cor-
rection of respiratory disturbance alone may not be
sufficient to entirely overcome complaints of fatigue
and daytime sleepiness in OSAS+RLS patients. Patho-
logical changes in central pathways (at subcortical
levels?), seen in RLS, could eventually have increased
sleep disruption, adding to fatigue and somnolence
and decreasing responsiveness to n-CPAP. It would
be interesting in the future and within a larger group
of patients, to study the influence of relative REM
sleep deprivation in this context. At this point it
would also be interesting to speculate on the need
to treat OSAS+RLS patients for respiratory and motor
symptoms separately, if the latter are to be consid-
ered a cause for the persistence of fatigue symptoms.
Additional studies are necessary to fully elucidate
these aspects, including a larger number of patients,
a longer follow-up period, and taking into account
other factors such as n-CPAP compliance. In our study
the compliance was evaluated (and reinforced)
through personal or phone contact, which may not
give a sufficient degree of certitude. A second poly-
somnographic evaluation would also be necessary
following the onset of n-CPAP treatment in order to
re-evaluate the macrostructure of sleep and compare
sleepiness more objectively.
In summary, the present study demonstrated that
the concomitant occurrence of RLS and OSAS does
not seem to be associated to a significantly distinct
basal clinical or laboratory OSAS profile. Following
n-CPAP treatment, a positive response in terms of a
decrease in fatigue and sleepiness scores was ob-
served in both groups. Nevertheless, OSAS and OSAS+
RLS patients responded differently to the n-CPAP
therapy, with higher residual fatigue and sleepiness
scores persisting in the OSAS+RLS group. Such find-
ing may be due to possible central dysfunctions
observed in RLS. Thus, there seems to be a need to
treat OSAS+RLS patients for both respiratory and
motor symptoms.
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